At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 609 enrolled
Drug / intervention
Erenumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334
In Brief
A Phase 2 clinical trial evaluating Erenumab for Treatment for Prevention of Chronic Migraine. Completed, enrolled 609 participants across 65 sites in 10 countries.
Detailed Summary
To assess the long-term safety and efficacy of erenumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Czechia, Denmark, Finland, Germany, Norway, Poland, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartJun 2014
Primary CompletionMay 2017
TodayJul 2026
First PostedJun 26, 2014
Enrollment StartJun 30, 2014
Primary CompletionMay 26, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.0 years ago
Interventions
Erenumabdrug
Administered by subcutaneous injection once a month